real-time news and commentary for investors
Wednesday, Mar 27
Navidea Biopharmaceuticals (NAVB +0.8%) bucks a weak tape after saying it's commenced enrollment...
Navidea Biopharmaceuticals (NAVB +0.8%) bucks a weak tape after saying it's commenced enrollment in Phase 2b positron emission tomography imaging studies of NAV4694, a scan for detecting cerebral-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment. The study is designed to investigate whether scan findings have the ability to distinguish between subjects with MCI who progress to Alzheimer's disease from those who do not.